Semaglutide vs Tirzepatide

Both are classed here as GLP-1 / incretin agonists, so this is a within-class choice: the mechanism is broadly shared and what separates them is kinetics, route, and how much has actually been tested.

The overlap is appetite control, fat loss, and metabolic health. On this site's goal weighting — an editorial priority score, not a measure of effect size — Semaglutide rates 4/5 for appetite control and Tirzepatide rates 5/5.

Neither has an evidence edge — both sit at the same tier. Semaglutide: an approved label and the randomized trial package behind it. Tirzepatide: an approved label and the randomized trial package behind it; head-to-head trials put its average weight loss above semaglutide. Anyone telling you one is clearly better supported than the other is going beyond what is published.

Semaglutide is a subcutaneous injection and taken by mouth; Tirzepatide is a subcutaneous injection. That is the difference most people actually feel: Tirzepatide means reconstituting a vial and injecting; Semaglutide does not require either. If needles are the deciding factor, this line settles it before any of the rest matters.

Half-lives are close — 7 days for Semaglutide, 5 days for Tirzepatide — and both are dosed once a week, so the rhythm of actually running them is the same.